Back to top

Image: Bigstock

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Read MoreHide Full Article

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company value investors might notice is Takeda Pharmaceutical Co. (TAK - Free Report) . TAK is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A.

Investors should also recognize that TAK has a P/B ratio of 0.85. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 1.15. TAK's P/B has been as high as 1.13 and as low as 0.80, with a median of 0.91, over the past year.

Finally, investors will want to recognize that TAK has a P/CF ratio of 6.73. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. TAK's current P/CF looks attractive when compared to its industry's average P/CF of 9.21. Over the past year, TAK's P/CF has been as high as 7.46 and as low as 4.11, with a median of 5.28.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Takeda Pharmaceutical Co. Is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, TAK feels like a great value stock at the moment.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Takeda Pharmaceutical Co. (TAK) - free report >>

Published in